Advertisement

Topics

BioMolecular Therapeutics, Inc. Company Profile

02:18 EDT 24th May 2017 | BioPortfolio

An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technology, asymmetric shorter-duplex siRNA (asiRNA). This novel RNAi technology significantly reduces deleterious side effects triggered by conventional siRNA, especially, the stimulation of the innate immune system, which makes it feasible to use asiRNA for the treatment of age-related macular degeneration, a disease to which RNAi therapeutics could not be developed using conventional siRNAs. Other potential applications for BMT's technology include therapeutics targeting infectious disease, such as herpes simplex virus (HSV), and cancer. A privately held company based in Suwon, South Korea, BMT was established in 2010.


News Articles [2047 Associated News Articles listed on BioPortfolio]

Biomolecular Analysis Expansion

RSSL's biomolecular analysis group has relocated to expanded laboratories at its JJT facility at Reading University.

RSSL expands biomolecular analysis facility

Reading Scientific Services Limited (RSSL) has relocated its biomolecular analysis group to expanded laboratories in its JTT facility on the Reading University site.

Single-molecule technique to explain thermodynamic behavior of complex biomolecular systems

Most thermodynamic measurements of binding reactions rely on the validity of the law of mass action and the assumption of a dilute solution. Yet, important biological systems such as allosteric ligand...

RSSL Release: Biomolecular Analysis Expansion

  Life Sciences Jobs   ...

Angela Brooks: Splicing Specialist

Assistant Professor, Department of Biomolecular Engineering University of California, Santa Cruz. Age: 34

Research Reports Initiation on Biotech Stocks -- Regulus Therapeutics, Abeona Therapeutics, ...

Regulus Therapeutics  San Diego, Californiaheadquartered Regulus Therapeutics Inc.'s stock finished Thursday's session 2.08% lower at $2.35with a total trading volume of 187,480 Read more...

CRISPR Therapeutics, Casebia Therapeutics partner with StrideBio

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeut...

New Microscopy Method Breaks Color Barrier of Optical Imaging

The innovative technique allows for the imaging of up to 24 biomolecular structures at a time instead of being limited by only five fluorescent proteins

Clinical Trials [115 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1137 Associated Companies listed on BioPortfolio]

Centre for Molecular and Biomolecular Informatics

Welcome at the CMBI, which is short for Centre for Molecular and Biomolecular Informatics. The centre performs research and education, and provides services in bioinformatics and cheminformatics.

Association of Biomolecular Resource Facilities

The Association of Biomolecular Resource Facilities is an international society dedicated to advancing core and research biotechnology laboratories through research, communication, and education.

BioMolecular Therapeutics, Inc.

An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technolo...

Affigen

Affigen (www.affigen.com) develops tumor-identifying therapeutics that target cell lineage-specific tumor proteins in certain incurable cancers. The Company's growing team ...

Aquasome

A platform nanoparticulate technology for biomolecular delivery in a broad range of industrial, personal use, and biomedical applications.

More Information about "BioMolecular Therapeutics, Inc." on BioPortfolio

We have published hundreds of BioMolecular Therapeutics, Inc. news stories on BioPortfolio along with dozens of BioMolecular Therapeutics, Inc. Clinical Trials and PubMed Articles about BioMolecular Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioMolecular Therapeutics, Inc. Companies in our database. You can also find out about relevant BioMolecular Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record